블로그
- [U.S. FDA] FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Chol proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density PCSK9 inhibitors have previously been available only as injectable therapies.
- Density of T-cell Subsets in Colorectal Cancer in Relation to Disease-Specific Survival Density of T-cell Subsets in Colorectal Cancer in Relation to Disease-Specific Survival Background: Prior studies have demonstrated that the overall density of T cells in colorectal tumors is favorably associated